AUD234.34
2.35% day before yesterday
Australia, Jun 27, 08:11 am CET
ISIN
AU000000CSL8
Symbol
CSL
Sector
Industry

CSL Stock price

AUD234.34
-14.65 5.88% 1M
-45.76 16.34% 6M
-44.99 16.11% YTD
-56.37 19.39% 1Y
-27.85 10.62% 3Y
-37.98 13.95% 5Y
+159.04 211.20% 10Y
+226.37 2,840.98% 20Y
Australia, Closing price Fri, Jun 27 2025
-5.64 2.35%
ISIN
AU000000CSL8
Symbol
CSL
Sector
Industry

Key metrics

Basic
Market capitalization
AUD116.2b
Enterprise Value
AUD132.2b
Net debt
AUD16.0b
Cash
AUD2.3b
Shares outstanding
484.2m
Valuation (TTM | estimate)
P/E
27.06 | 23.36
P/S
4.98 | 4.79
EV/Sales
5.67 | 5.45
EV/FCF
46.30
P/B
3.99
Dividends
DPS
AUD5.12
Yield 1Y | 5Y
2.19% | 1.32%
Growth 1Y | 5Y
41.14% | 14.02%
Payout 1Y | 3Y
61.42% | 52.71%
Increased
3 Years
Financials (TTM | estimate)
Revenue
AUD23.3b | AUD24.3b
EBITDA
AUD7.5b | AUD8.1b
EBIT
AUD6.0b
Net Income
AUD4.2b | AUD4.9b
Free Cash Flow
AUD2.9b
Growth (TTM | estimate)
Revenue
7.41% | 7.11%
EBITDA
8.22% | 25.91%
EBIT
7.28%
Net Income
11.16% | 20.10%
Free Cash Flow
60.97%
Margin (TTM | estimate)
Gross
51.80%
EBITDA
32.22% | 33.53%
EBIT
25.75%
Net
18.04% | 20.01%
Free Cash Flow
12.25%
Financial Health
Equity Ratio
45.67%
Return on Equity
15.22%
ROCE
12.12%
ROIC
9.44%
Debt/Equity
0.64
More
EPS
AUD8.66
FCF per Share
AUD5.90
Short interest
-
Employees
32.70k
Rev per Employee
AUD690.00k
Show more

Is CSL a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

CSL Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a CSL forecast:

18x Buy
86%
3x Hold
14%

Analyst Opinions

21 Analysts have issued a CSL forecast:

Buy
86%
Hold
14%

Financial data from CSL

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
23,316 23,316
7% 7%
100%
- Direct Costs 11,239 11,239
7% 7%
48%
12,077 12,077
8% 8%
52%
- Selling and Administrative Expenses 3,921 3,921
7% 7%
17%
- Research and Development Expense 2,152 2,152
4% 4%
9%
7,512 7,512
8% 8%
32%
- Depreciation and Amortization 1,508 1,508
12% 12%
6%
EBIT (Operating Income) EBIT 6,004 6,004
7% 7%
26%
Net Profit 4,207 4,207
11% 11%
18%

In millions AUD.

Don't miss a Thing! We will send you all news about CSL directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment provides plasma products, gene therapies, and recombinants. The CSL Seqirus segment includes predominantly influenza related products and provides pandemic services to governments. The CSL Vidor segment focuses on the distribution of products in the therapeutic areas of iron deficiency and nephrology. The company was founded on November 2, 1961 and is headquartered in Melbourne, Australia.

Head office Australia
CEO Paul McKenzie
Employees 32,698
Founded 1961
Website www.csl.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today